Microbial Enzymes Catalyzing Keratin Degradation: Classification, Structure, Function
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Structure of SARS-Cov-2 Main Protease in the Apo State Reveals the 2 Inactive Conformation 3
bioRxiv preprint doi: https://doi.org/10.1101/2020.05.12.092171; this version posted May 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Structure of SARS-CoV-2 main protease in the apo state reveals the 2 inactive conformation 3 4 Xuelan Zhoua,1, Fangling Zhongb,c,1, Cheng Lind,e, Xiaohui Hua, Yan Zhangf, Bing Xiongg, 5 Xiushan Yinh,i, Jinheng Fuj, Wei Heb, Jingjing Duank, Yang Ful, Huan Zhoum, Qisheng Wang 6 m,*, Jian Li b,c,*, Jin Zhanga,* 7 8 a School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, 330031, China. 9 b College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, Jiangxi, 10 PR, China. 11 c Laboratory of Prevention and treatment of cardiovascular and cerebrovascular diseases, 12 Ministry of Education, Gannan Medical University, Ganzhou 341000, PR China 13 d Shenzhen Crystalo Biopharmaceutical Co., Ltd, Shenzhen, Guangdong, 518118, China 14 e Jiangxi Jmerry Biopharmaceutical Co., Ltd, Ganzhou, Jiangxi, 341000, China. 15 f The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330031, China 16 g Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese 17 Academy of Sciences, 555 Zuchongzhi Road , Shanghai 201203 , China. 18 h Applied Biology Laboratory, Shenyang University of Chemical Technology, 110142, 19 Shenyang, China 20 i Biotech & Biomedicine Science (Jiangxi)Co. Ltd, Ganzhou, 341000, China 21 j Jiangxi-OAI Joint -
Mechanistic Insights Into the Inhibition of Prostate Specific Antigen by [Beta
proteins STRUCTURE O FUNCTION O BIOINFORMATICS Mechanistic insights into the inhibition of prostate specific antigen by b-lactam class compounds Pratap Singh,1,2* Simon A. Williams,2 Meha H. Shah,3 Thomas Lectka,3 Gareth J. Pritchard,4 John T. Isaacs,2 and Samuel R. Denmeade1,2 1 Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, Maryland 21218 2 Chemical Therapeutics Program, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 3 Department of Chemistry, Johns Hopkins University, Baltimore, Maryland 21218 4 Department of Chemistry, Loughborough University, Loughborough, Leicestershire LE11 3TU, United Kingdom ABSTRACT for the effect of stereochemistry of the lactam ring on the in- hibitory potency was elucidated through docking of b-lactam Prostate Specific Antigen (PSA) is a biomarker used in the enantiomers. As a validation of our docking methodology, diagnosis of prostate cancer and to monitor therapeutic two novel enantiomers were synthesized and evaluated for response. However, its precise role in prostate carcinogenesis their inhibitory potency using fluorogenic substrate based ac- and metastasis remains largely unknown. A number of stud- tivity assays. Additionally, cis enantiomers of eight b-lactam ies arguing in the favor of an active role of PSA in prostate compounds reported in a previous study were docked and cancer development and progression have implicated this their GOLD scores -
Nardilysin Is Involved in Autoimmune Arthritis Via the Regulation of Tumour Necrosis Factor Alpha Secretion
Animal models RMD Open: first published as 10.1136/rmdopen-2017-000436 on 13 July 2017. Downloaded from ORIGINAL articLE Nardilysin is involved in autoimmune arthritis via the regulation of tumour necrosis factor alpha secretion Takayuki Fujii,1 Eiichiro Nishi,2,3 Hiromu Ito,1 Hiroyuki Yoshitomi,4 Moritoshi Furu,5 Namiko Okabe,6 Mikiko Ohno,2 Kiyoto Nishi,2 Yusuke Morita,2 Yugo Morita,1 Masayuki Azukizawa,1 Akinori Okahata,1 Takuya Tomizawa,1 Takeshi Kimura,2 Shuichi Matsuda1 To cite: Fujii T, Nishi E, ABSTRACT Key messages Ito H, et al. Nardilysin is Objective Tumour necrosis factor alpha (TNF-α) plays involved in autoimmune an important role in rheumatoid arthritis (RA). TNF-α is arthritis via the regulation synthesised as a membrane-anchored precursor and is What is already known about this subject? of tumour necrosis factor fully activated by a disintegrin and metalloproteinase 17 ► Tumour necrosis factor alpha (TNF-α), which alpha secretion. RMD Open (ADAM17)-mediated ectodomain shedding. Nardilysin is activated by ectodomain shedding, plays an 2017;3:e000436. doi:10.1136/ important role in rheumatoid arthritis (RA). rmdopen-2017-000436 (NRDC) facilitates ectodomain shedding via activation of ADAM17. This study was undertaken to elucidate the role ► Nardilysin facilitates TNF-α shedding via enhancing of NRDC in RA. a disintegrin and metalloproteinase 17 activity. Additional material is –/– ► Methods NRDC-deficient Nrdc( ) mice and macrophage- published online only. To view What does this study add? specific NRDC-deficientNrdc ( delM) mice were examined please visit the journal online ► Deletion or inhibition of nardilysin prevents (http:// dx. doi. org/ 10. -
Determining the Catalytic Role of Remote Substrate Binding Interactions in Ketosteroid Isomerase
Determining the catalytic role of remote substrate binding interactions in ketosteroid isomerase Jason P. Schwans1, Daniel A. Kraut1, and Daniel Herschlag2 Department of Biochemistry, Stanford University, Stanford, CA 94305 Edited by Vern L. Schramm, Albert Einstein College of Medicine, Bronx, NY, and approved June 24, 2009 (received for review February 2, 2009) A fundamental difference between enzymes and small chemical with substrate binding solvent is displaced and excluded from the catalysts is the ability of enzymes to use binding interactions with active site and solvent exclusion may be important in shaping the nonreactive portions of substrates to accelerate chemical reactions. electrostatic environment within the active site (26, 27). Indeed, Remote binding interactions can localize substrates to the active solvent exclusion by substrate binding has been suggested to be site, position substrates relative to enzymatic functional groups important for catalysis in numerous enzymes (e.g., refs. 26–32). and other substrates, trigger conformational changes, induce local Jencks and others realized that remote binding interactions destabilization, and modulate an active site environment by sol- can do more than provide for tight binding between substrate vent exclusion. We investigated the role of remote substrate and enzyme. Reactions of bound substrates can be facilitated by binding interactions in the reaction catalyzed by the enzyme use of so-called ‘‘intrinsic binding energy’’, which can pay for ketosteroid isomerase (KSI), which catalyzes a double bond migra- substrate desolvation, distortion, electrostatic destabilization, tion of steroid substrates through a dienolate intermediate that is and entropy loss (3, 7, 33, 34). The term intrinsic binding energy stabilized in an oxyanion hole. -
Functional Coverage of the Human Genome by Existing Structures, Structural Genomics Targets, and Homology Models
Functional Coverage of the Human Genome by Existing Structures, Structural Genomics Targets, and Homology Models Lei Xie, Philip E. Bourne* San Diego Supercomputer Center and Department of Pharmacology, University of California, San Diego, California, United States of America The bias in protein structure and function space resulting from experimental limitations and targeting of particular functional classes of proteins by structural biologists has long been recognized, but never continuously quantified. Using the Enzyme Commission and the Gene Ontology classifications as a reference frame, and integrating structure data from the Protein Data Bank (PDB), target sequences from the structural genomics projects, structure homology derived from the SUPERFAMILY database, and genome annotations from Ensembl and NCBI, we provide a quantified view, both at the domain and whole-protein levels, of the current and projected coverage of protein structure and function space relative to the human genome. Protein structures currently provide at least one domain that covers 37% of the functional classes identified in the genome; whole structure coverage exists for 25% of the genome. If all the structural genomics targets were solved (twice the current number of structures in the PDB), it is estimated that structures of one domain would cover 69% of the functional classes identified and complete structure coverage would be 44%. Homology models from existing experimental structures extend the 37% coverage to 56% of the genome as single domains and 25% to 31% for complete structures. Coverage from homology models is not evenly distributed by protein family, reflecting differing degrees of sequence and structure divergence within families. While these data provide coverage, conversely, they also systematically highlight functional classes of proteins for which structures should be determined. -
The Ectodomain Shedding Database for Membrane-Bound Shed Markers Wei-Sheng Tien1,2, Jun-Hong Chen3 and Kun-Pin Wu1*
The Author(s) BMC Bioinformatics 2017, 18(Suppl 3):42 DOI 10.1186/s12859-017-1465-7 RESEARCH Open Access SheddomeDB: the ectodomain shedding database for membrane-bound shed markers Wei-Sheng Tien1,2, Jun-Hong Chen3 and Kun-Pin Wu1* From The Fifteenth Asia Pacific Bioinformatics Conference Shenzhen, China. 16-18 January 2017 Abstract Background: A number of membrane-anchored proteins are known to be released from cell surface via ectodomain shedding. The cleavage and release of membrane proteins has been shown to modulate various cellular processes and disease pathologies. Numerous studies revealed that cell membrane molecules of diverse functional groups are subjected to proteolytic cleavage, and the released soluble form of proteins may modulate various signaling processes. Therefore, in addition to the secreted protein markers that undergo secretion through the secretory pathway, the shed membrane proteins may comprise an additional resource of noninvasive and accessible biomarkers. In this context, identifying the membrane-bound proteins that will be shed has become important in the discovery of clinically noninvasive biomarkers. Nevertheless, a data repository for biological and clinical researchers to review the shedding information, which is experimentally validated, for membrane-bound protein shed markers is still lacking. Results: In this study, the database SheddomeDB was developed to integrate publicly available data of the shed membrane proteins. A comprehensive literature survey was performed to collect the membrane proteins that were verified to be cleaved or released in the supernatant by immunological-based validation experiments. From 436 studies on shedding, 401 validated shed membrane proteins were included, among which 199 shed membrane proteins have not been annotated or validated yet by existing cleavage databases. -
Enzyme DHRS7
Toward the identification of a function of the “orphan” enzyme DHRS7 Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Selene Araya, aus Lugano, Tessin Basel, 2018 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Alex Odermatt (Fakultätsverantwortlicher) und Prof. Dr. Michael Arand (Korreferent) Basel, den 26.6.2018 ________________________ Dekan Prof. Dr. Martin Spiess I. List of Abbreviations 3α/βAdiol 3α/β-Androstanediol (5α-Androstane-3α/β,17β-diol) 3α/βHSD 3α/β-hydroxysteroid dehydrogenase 17β-HSD 17β-Hydroxysteroid Dehydrogenase 17αOHProg 17α-Hydroxyprogesterone 20α/βOHProg 20α/β-Hydroxyprogesterone 17α,20α/βdiOHProg 20α/βdihydroxyprogesterone ADT Androgen deprivation therapy ANOVA Analysis of variance AR Androgen Receptor AKR Aldo-Keto Reductase ATCC American Type Culture Collection CAM Cell Adhesion Molecule CYP Cytochrome P450 CBR1 Carbonyl reductase 1 CRPC Castration resistant prostate cancer Ct-value Cycle threshold-value DHRS7 (B/C) Dehydrogenase/Reductase Short Chain Dehydrogenase Family Member 7 (B/C) DHEA Dehydroepiandrosterone DHP Dehydroprogesterone DHT 5α-Dihydrotestosterone DMEM Dulbecco's Modified Eagle's Medium DMSO Dimethyl Sulfoxide DTT Dithiothreitol E1 Estrone E2 Estradiol ECM Extracellular Membrane EDTA Ethylenediaminetetraacetic acid EMT Epithelial-mesenchymal transition ER Endoplasmic Reticulum ERα/β Estrogen Receptor α/β FBS Fetal Bovine Serum 3 FDR False discovery rate FGF Fibroblast growth factor HEPES 4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid HMDB Human Metabolome Database HPLC High Performance Liquid Chromatography HSD Hydroxysteroid Dehydrogenase IC50 Half-Maximal Inhibitory Concentration LNCaP Lymph node carcinoma of the prostate mRNA Messenger Ribonucleic Acid n.d. -
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants. -
Substrate and Nucleotide
ClpX interactions with ClpP, SspB, protein substrate and nucleotide by OF ECHNOLOGY Greg Louis Hersch FEB 0 1RIE2006 B.S. Biochemistry LIBRAR IES University of California at Davis, 2001 Submitted to the Department of Biology in partial fulfillment of the requirementsfor the degreeof Doctor of Philosophy in Biochemistry McM0.l at the Massachusetts Institute of Technology February 2006 © 2005 Greg L. Hersch. All rights reserved The authors herebygrants to MITpermission to reproduceand to distributepublicly Paper and electronic copies of the thesis document in whole or in part. Signature of Author: .1 - · -- - Department of Biology Certified by: I/ Robert T. Sauer Salvador E. Luria Professor of Biology Thesis Supervisor Accepted by: / - t R11 (_2~ ,tenhen P RPellI Professor of Biology Co-Chair, Biology Graduate Committee CIpX interactions with CIpP, SspB, protein substrate and nucleotide By Greg Louis Hersch Submitted to the Department of Biology on February 6th, 2006 in partial fulfillment of the requirements for the degree of doctor of philosophy in biochemistry ABSTRACT ClpXP and related ATP-dependent proteases are implements of cytosolic protein destruction. They couple chemical energy, derived from ATP hydrolysis, to the selection, unfolding, and degradation of protein substrates with the appropriate degradation signals. The ClpX component of ClpXP is a hexameric enzyme that recognizes protein substrates and unfolds them in an ATP-dependent reaction. Following unfolding, ClpX translocates the unfolded substrate into the ClpP peptidase for degradation. The best characterized degradation signal is the ssrA-degradation tag, which contains a binding site for ClpX and an adjacent binding site for the SspB adaptor protein. I show that the close proximity of these binding elements causes SspB binding to mask signals needed for ssrA-tag recognition by ClpX. -
The Crotonase Superfamily: Divergently Related Enzymes That Catalyze Different Reactions Involving Acyl Coenzyme a Thioesters
Acc. Chem. Res. 2001, 34, 145-157 similar three-dimensional architectures. In each protein, The Crotonase Superfamily: a common structural strategy is employed to lower the Divergently Related Enzymes free energies of chemically similar intermediates. Catalysis of the divergent chemistries is accomplished by both That Catalyze Different retaining those functional groups that catalyze the com- mon partial reaction and incorporating new groups that Reactions Involving Acyl direct the intermediate to new products. Indeed, as a Coenzyme A Thioesters specific example, the enolase superfamily has served as a paradigm for the study of catalytically diverse superfami- HAZEL M. HOLDEN,*,³ lies.3 The active sites of proteins in the enolase superfamily MATTHEW M. BENNING,³ are located at the interfaces between two structural TOOMAS HALLER,² AND JOHN A. GERLT*,² motifs: the catalytic groups are positioned in conserved Departments of Biochemistry, University of Illinois, regions at the ends of the â-strands forming (R/â) 8-barrels, Urbana, Illinois 61801, and University of Wisconsin, while the specificity determinants are found in flexible Madison, Wisconsin 53706 loops in the capping domains formed by the N- and Received August 9, 2000 C-terminal portions of the polypeptide chains. While the members of the enolase superfamily share similar three- ABSTRACT dimensional architectures, they catalyze different overall Synergistic investigations of the reactions catalyzed by several reactions that share a common partial reaction: abstrac- members of an enzyme superfamily provide a more complete tion of an R-proton from a carboxylate anion substrate understanding of the relationships between structure and function than is possible from focused studies of a single enzyme alone. -
Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48 -
Proteolytic Cleavage—Mechanisms, Function
Review Cite This: Chem. Rev. 2018, 118, 1137−1168 pubs.acs.org/CR Proteolytic CleavageMechanisms, Function, and “Omic” Approaches for a Near-Ubiquitous Posttranslational Modification Theo Klein,†,⊥ Ulrich Eckhard,†,§ Antoine Dufour,†,¶ Nestor Solis,† and Christopher M. Overall*,†,‡ † ‡ Life Sciences Institute, Department of Oral Biological and Medical Sciences, and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada ABSTRACT: Proteases enzymatically hydrolyze peptide bonds in substrate proteins, resulting in a widespread, irreversible posttranslational modification of the protein’s structure and biological function. Often regarded as a mere degradative mechanism in destruction of proteins or turnover in maintaining physiological homeostasis, recent research in the field of degradomics has led to the recognition of two main yet unexpected concepts. First, that targeted, limited proteolytic cleavage events by a wide repertoire of proteases are pivotal regulators of most, if not all, physiological and pathological processes. Second, an unexpected in vivo abundance of stable cleaved proteins revealed pervasive, functionally relevant protein processing in normal and diseased tissuefrom 40 to 70% of proteins also occur in vivo as distinct stable proteoforms with undocumented N- or C- termini, meaning these proteoforms are stable functional cleavage products, most with unknown functional implications. In this Review, we discuss the structural biology aspects and mechanisms